AstraZeneca OLAPARIB – Ovarian Cancer Drug Gets Approval In US

December 19, 2014 11:11 PM

5 0

Astrazeneca Plc (AZN) won accelerated-approval in the United States for an ovarian cancer medication that the organization once had scrapped.

The Food and Drug Administration cleared the treatment, Lynparza, for women with the advanced ovarian cancer who hold a hereditary genetic mutation, an announcement from the agency revealed today. The medication is planned for patients who already have been greatly treated with different treatments.

Read more

To category page

Loading...